CN104958301A - 一种抑制剂ly294002的用途 - Google Patents
一种抑制剂ly294002的用途 Download PDFInfo
- Publication number
- CN104958301A CN104958301A CN201510339728.1A CN201510339728A CN104958301A CN 104958301 A CN104958301 A CN 104958301A CN 201510339728 A CN201510339728 A CN 201510339728A CN 104958301 A CN104958301 A CN 104958301A
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- brucella melitensis
- pi3k
- cell
- brucella
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510339728.1A CN104958301A (zh) | 2015-06-18 | 2015-06-18 | 一种抑制剂ly294002的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510339728.1A CN104958301A (zh) | 2015-06-18 | 2015-06-18 | 一种抑制剂ly294002的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104958301A true CN104958301A (zh) | 2015-10-07 |
Family
ID=54212508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510339728.1A Pending CN104958301A (zh) | 2015-06-18 | 2015-06-18 | 一种抑制剂ly294002的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104958301A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113667711A (zh) * | 2020-05-14 | 2021-11-19 | 复旦大学 | 一种基于自噬-外泌通路调节巨噬细胞极化的方法及其用途 |
-
2015
- 2015-06-18 CN CN201510339728.1A patent/CN104958301A/zh active Pending
Non-Patent Citations (6)
Title |
---|
JUNBO ZHANG ET AL.: "Activation of the PI3K/Akt Pathway is Essential for the Survival of Brucella melitensis 16M In Vitro and In Vivo", 《PAKISTAN VETERINARY JOURNAL》 * |
印双红等: "PI3K/Akt信号通路对布鲁氏菌介导的细胞凋亡基因表达的影响", 《安徽农业科学》 * |
印双红等: "抑制剂LY294002调控胞内布鲁氏菌的存活", 《生物技术》 * |
张俊波: "《中国博士学位论文全文数据库(电子期刊)农业科技辑》", 15 January 2016 * |
张俊波等: "PI3K/Akt信号通路在胞内布鲁氏菌存活中的作用", 《江苏农业科学》 * |
张俊波等: "羊种布鲁氏杆菌16M对PI3K/Akt信号通路的激活", 《黑龙江畜牧兽医科技版》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113667711A (zh) * | 2020-05-14 | 2021-11-19 | 复旦大学 | 一种基于自噬-外泌通路调节巨噬细胞极化的方法及其用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lee et al. | Lactobacillus suntoryeus inhibits pro-inflammatory cytokine expression and TLR-4-linked NF-κB activation in experimental colitis | |
Preising et al. | Selection of bifidobacteria based on adhesion and anti-inflammatory capacity in vitro for amelioration of murine colitis | |
Chen et al. | Baicalin, baicalein, and Lactobacillus rhamnosus JB3 alleviated Helicobacter pylori infections in vitro and in vivo | |
Song et al. | What roles do probiotics play in the eradication of Helicobacter pylori? Current knowledge and ongoing research | |
Liang et al. | The roles of adipose tissue macrophages in human disease | |
CN111110703B (zh) | 动物双歧杆菌及其制备的复合菌制剂在制备治疗或预防禽流感病毒感染的药物中的应用 | |
KR102403453B1 (ko) | 헬리코박터 파이로리 감염의 관리를 위한 조성물 | |
WO2013135192A1 (zh) | 百秋李醇的新用途 | |
Tsurita et al. | Early augmentation of interleukin (IL)-12 level in the airway of mice administered orally with clarithromycin or intranasally with IL-12 results in alleviation of influenza infection | |
Shukla et al. | Comparative therapeutic effect of probiotic Lactobacillus casei alone and in conjunction with antiprotozoal drugs in murine giardiasis | |
Yue et al. | Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease | |
Cremonini et al. | Helicobacter pylori treatment: a role for probiotics? | |
Higgins et al. | Recurrent Kaposi's varicelliform eruption in Darier's disease | |
Ahsan et al. | Emergence of high colistin resistance in carbapenem resistant Acinetobacter baumannii in Pakistan and its potential management through immunomodulatory effect of an extract from Saussurea lappa | |
CN104958301A (zh) | 一种抑制剂ly294002的用途 | |
CN111705041B (zh) | 一株哈维氏弧菌噬菌体vB_KaS_PK22、其噬菌体组合物及其应用 | |
Luo et al. | Isolation, genomic analysis, and preliminary application of a bovine Klebsiella pneumoniae bacteriophage vB_Kpn_B01 | |
CN111676197B (zh) | 一株哈维氏弧菌噬菌体、其噬菌体组合物及其应用 | |
Minagawa et al. | Activation of natural killer T cells by α-galactosylceramide mediates clearance of bacteria in murine urinary tract infection | |
Guo et al. | The combined effect of a novel formula of herbal extracts on bacterial infection and immune response in Micropterus salmoides | |
KR101344218B1 (ko) | 페노피브레이트를 함유하는 결핵 치료용 약학 조성물 | |
CN106913569A (zh) | 苯酞类化合物在制备抗耐药菌药物中的应用 | |
Luan et al. | Inhibition of drug resistance of Staphylococcus aureus by efflux pump inhibitor and autolysis inducer to strengthen the antibacterial activity of β-lactam drugs | |
WO2018227734A1 (zh) | 趋化因子CXCL16与肿瘤坏死因子-α在制备治疗弥漫大B细胞淋巴瘤药物中的应用 | |
CN109200063A (zh) | 脆弱拟杆菌在制备用于治疗和预防结核病的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Junbo Inventor after: Yin Shuanghong Inventor after: Luo Jing Inventor after: Li Jianxin Inventor after: Ran Hui Inventor after: Li Mo Inventor before: Shu Hua Inventor before: Yao Yuanyong Inventor before: Tang Bangcheng Inventor before: Xie Zinan Inventor before: Wu Sizhan |
|
COR | Change of bibliographic data | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151007 |
|
RJ01 | Rejection of invention patent application after publication |